Panobinostat (LBH589)

For research use only.

Catalog No.S1030 Synonyms: NVP-LBH589

252 publications

Panobinostat (LBH589) Chemical Structure

CAS No. 404950-80-7

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 114 In stock
EUR 88 In stock
EUR 265 In stock
EUR 658 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Panobinostat (LBH589) has been cited by 252 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NVHjb29PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\0Uow6OC1zMDFOwG0> NXj5doE4OC12IHS= MnTKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1nnOVI3PzB{N{i0
HepG2 NUnC[Y5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7iSWU6OC1zMDFOwG0> MnHBNE01KGR? NHvNeVNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MkXrNlY4ODJ5OES=
HT29 MWHGeY5kfGmxbjDBd5NigQ>? NXXCV5NzPTEEoH7N MWSyOE04OiCq NYDxWXhucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB2ONMgbOKh NULT[Yk1OjZ5MEK3PFQ>
HepG2 MVTGeY5kfGmxbjDBd5NigQ>? M2L5XVUxyqCwTR?= MoDSNlQuPzJiaB?= NX\RZo9qcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB{NNMgbOKh MnPNNlY4ODJ5OES=
HCC827 NU[3SpN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXETnY6PS95LkWvNVAhdk1? M{PBcVczyqCq M1Hyd2ROW09? M3\PRoVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk MVuyOlY4PTR6NB?=
A549  NV\QOG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXIb4N2OTBxMUWvNlAhdk1? M3\1PFczyqCq NGPXNHdFVVOR NF\zcGVmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= M164U|I3Pjd3NEi0
NCI-H460  NVS4O2xzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LTfVExNzJyL{OwJI5O NU\Jd2ZqPzMEoHi= NGrMdFhFVVOR MV;lcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NVzFZ21oOjZ4N{W0PFQ>
J89GFP NUPmeG5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELqboZFVVORwrC= NXfRW|lJTUN3ME20PU45PSEEsTCxNk43PSCwTR?= MVuyOlU3OzV4OB?=
THP89GFP MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe1UHFFVVORwrC= MYnFR|UxRTF7LkO0JOKyKDZwNEOgcm0> M37LV|I3PTZ|NU[4
SK-NEP-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPScHIxNjBz4pETNVAvOCEQvF2= NGrjcHozPCCq MnjaSG1UV8Li M2S3VGlEPTB;N{[uN|Qhdk1? MlvkNlYyPzZ{MUm=
G401 M1vFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrGNE4xOeLCk{GwMlAh|ryP NGHZU|czPCCq MlrkSG1UV8Li M3G3V2lEPTB;MUSzMlAzKG6P MnvYNlYyPzZ{MUm=
SK-NEP-1 MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVjuS2IyPTBibl2= NHzMfIoy6oDVNDDk MnjZSG1UV8Li M37IZ5Jm\HWlZYOgZ4VtdCC|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NWrxVJk6OjZzN{[yNVk>
G401 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYi1NEBvVQ>? MlfJNgKBmzRiZB?= Mkn6SG1UV8Li MY\y[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> Mm[xNlYyPzZ{MUm=
SK-NEP-1 MVfBdI9xfG:|aYOgRZN{[Xl? Ml3QOVAwOTByIH7N NYLSSGQyOjRiaB?= M1L2dWROW00EoB?= NGHCUZRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYOyOlE4PjJzOR?=
G401 MUPBdI9xfG:|aYOgRZN{[Xl? NWHKWIs4PTBxMUCwJI5O MYeyOEBp M32yU2ROW00EoB?= MnP2bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWGyOlE4PjJzOR?=
SK-NEP-1 NIXpbGJHfW6ldHnvckBCe3OjeR?= NEHk[og2OC9zMECgcm0> MkXwNlQhcA>? MoPlSG1UV8Li MW\zbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v NVP0Xm1JOjZzN{[yNVk>
G401 M2TORWZ2dmO2aX;uJGF{e2G7 M2K5dFUxNzFyMDDuUS=> NFH0SHEzPCCq NILhZVdFVVORwrC= M4L4eZNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? NXnCcXh6OjZzN{[yNVk>
SK-NEP-1 MU\GeY5kfGmxbjDBd5NigQ>? NIG1flM2OC9zMECgcm0> M4nlVFI1KGh? MWrEUXNQyqB? MVjpcoR2[2W|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=> NHrONGkzPjF5NkKxPS=>
G401 NIHKZnpHfW6ldHnvckBCe3OjeR?= NHnwVXg2OC9zMECgcm0> NWHFZndzOjRiaB?= M3jUZ2ROW00EoB?= NGPvNHVqdmS3Y3XzJINmdGxiY4njcIUh\Gm|b4Lk[ZLDqA>? M4P5SlI3OTd4MkG5
RPMI 8226 NYLPbnk6S2WubDDTeZJ3cX[jbDDBd5NigQ>? NHHUOHEzNzRxNjDuUS=> MWq0PQKBkWh? NGLoUmNqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NFvnT2QzPjByMEK5Ni=>
OPM2 NFvUWWNE\WyuIGP1dpZqfmGuIFHzd4F6 MXSyM|QwPiCwTR?= MoLEOFjjiImq NH;qdmJqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NHvkOGUzPjByMEK5Ni=>
U266 MV7D[YxtKFO3co\peoFtKEG|c3H5 M4O5TVIwPC94IH7N MVy0PQKBkWh? NFvlfopqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NGrFXVMzPjByMEK5Ni=>
H929 M3LP[GNmdGxiU4Xyeol3[WxiQYPzZZk> MoC2Nk81NzZibl2= MYi0PQKBkWh? MnPObY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? MVGyOlAxODJ7Mh?=
RPMI 8226  NEXJWpRCeG:ydH;zbZMhSXO|YYm= MlPYOQKBkW6P NVvrVYs4OjRxNEigbC=> MkLqbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MUWyOlAxODJ7Mh?=
HCC827 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojKNVAhdk1? M2Pyd|Q5KGh? NF\qbJFFVVOR Ml7l[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB? M3\qe|I2QTR2NkG3
NCI-H23 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nWVVExKG6P MY[0PEBp NVuzR3h[TE2VTx?= MVLlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? NIG3fY4zPTl2NE[xOy=>
AML3 NFfIVotHfW6ldHnvckBCe3OjeR?= M2TySFAuOSEQvF2= NWG4Oo5oOjUEoHi= M4rp[4lv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHrDNYwzPTZzMkm0NS=>
ML-1 MkLpSpVv[3Srb36gRZN{[Xl? MXKwMVEh|ryP NYnt[XlPOjUEoHi= MU\pcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MnrENlU3OTJ7NEG=
RPMI-8226vr10  MYPGeY5kfGmxbjDBd5NigQ>? MYGwMVEh|ryP MYOyOOKhcA>? MXXpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2LsOFI2PjF{OUSx
ML-1 NGjNdGhHfW6ldHnvckBCe3OjeR?= NGjOPG4yKM7:TR?= NYTONWNsOjUEoHi= NG\3WJVqdmO{ZXHz[ZMh[2G|cHHz[U0{KGGldHn2bZR6KDRvZn;s[C=> Ml\iNlU3OTJ7NEG=
RPMI-8226vr10  NWLad|B1TnWwY4Tpc44hSXO|YYm= MmHRNUDPxE1? NXXHOXNzOjUEoHi= NYLPZ3RicW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB{LkWt[o9t\A>? NGXh[4wzPTZzMkm0NS=>
SK-N-BE (2) NFq2dJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2yOQKBkWh? MofBTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P MkjONlU{ODh7MU[=
SK-N-BE (2), PAN  MK MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFGxWWczPOLCiXi= MlLxTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P NHTN[|kzPTNyOEmxOi=>
SK-N-BE (2), MK  PAN Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6yOQKBkWh? MorSTWM2OD1|OEKuNQKBkcLz4pEJOFMvOiCwTR?= NYT3N3B2OjV|MEi5NVY>
SK-N-AS M2q0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jCfVI16oDLaB?= NViwS4NQUUN3ME2zO{4y6oDLwsJihKkzNjRibl2= MU[yOVMxQDlzNh?=
SK-N-DZ MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HUO|I16oDLaB?= M37DPGlEPTB;MUeuNgKBkcLz4pEJNE41KG6P NEXjU5QzPTNyOEmxOi=>
Caki-1 NH3yfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInQeIgyOC9{NT:1NEBvVQ>? NX\2c3BOPDhiaB?= Mn2xbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MXuyOVI4QTF7MR?=
ACHN MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLDNVAwOjVxNUCgcm0> M3vsUFQ5KGh? NIPEeZpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= M{H6SVI2Ojd7MUmx
769-P NUTOTGdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi1N|FjOTBxMkWvOVAhdk1? NWHLW|RXPDhiaB?= MlHpbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ NIXwb|YzPTJ5OUG5NS=>
786-O  MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fPUlExNzJ3L{WwJI5O Mly3OFghcA>? NGrsWJVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= M4TsdFI2Ojd7MUmx
Caki-1 NWDtbFFuSXCxcITvd4l{KEG|c3H5 M2XIO|UxKG6P M13tfVQ5KGh? NITxfItqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= Moi2NlUzPzlzOUG=
ACHN M33PUGFxd3C2b4Ppd{BCe3OjeR?= NGj0UYI2OCCwTR?= NE\aOGo1QCCq NH7LXm5qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= MUCyOVI4QTF7MR?=
769-P NX[yZpNtSXCxcITvd4l{KEG|c3H5 MVy1NEBvVQ>? MmqyOFghcA>? MVHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? MX6yOVI4QTF7MR?=
786-O  MoDLRZBweHSxc3nzJGF{e2G7 MYW1NEBvVQ>? NV\Mepp4PDhiaB?= MmDabY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? Mnn0NlUzPzlzOUG=
Caki-1 NYjMcHRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfnRZozPS93MDDuUS=> MWC0PEBp NHziU3ZFVVOR NGP5RYZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni NI[w[20zPTF5NkO1OC=>
ACHN MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzZNlUwPTBibl2= NXG2XVZFPDhiaB?= M3rL[GROW09? NVv1W4F3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> MWSyOVE4PjN3NB?=
769-P MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnqblkzPS93MDDuUS=> MkfLOFghcA>? MmPrSG1UVw>? NXf3fVVWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> NEP4PYMzPTF5NkO1OC=>
Caki-1 MWrDc4xwdnliRn;ycYF1cW:wIFHzd4F6 MnPqOVAhdk1? MlHkO{0yPCCm MULEUXNQ NF70fmR{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? M{fsVlI2OTd4M{W0
ACHN M2qxUWNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? NV7NTWlUPTBibl2= M3PzNlcuOTRiZB?= Mle4SG1UVw>? M37qW5N2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh NVnSTocxOjVzN{[zOVQ>
769-P MXHDc4xwdnliRn;ycYF1cW:wIFHzd4F6 M2\xOVUxKG6P MoLoO{0yPCCm NF;KbZdFVVOR MoLod5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> NVXURXkyOjVzN{[zOVQ>
Caki-1 NWTkZ3BISXCxcITvd4l{KEG|c3H5 NY\jbItFPTBibl2= MUm0PEBp M2LKdmROW09? M1jCeYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NHmwe4MzPTF5NkO1OC=>
ACHN MWHBdI9xfG:|aYOgRZN{[Xl? Mmq0OVAhdk1? NFnO[YE1QCCq M1nRd2ROW09? M4LHfYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NIjVbIkzPTF5NkO1OC=>
769-P NFvFfoRCeG:ydH;zbZMhSXO|YYm= NHq0WnY2OCCwTR?= NEfINmc1QCCq M4nYcmROW09? MkXhbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M{HLPVI2OTd4M{W0
MDA-MB-231 MmDPUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 NX\GTHBmOTEEoH7N MkS3N:Kh\A>? M{[0V2ROW09? MWLhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? NWfubllmOjR6MUC0PVc>
BT-549 MliyUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 MUSxNOKhdk1? NH7z[48{yqCm NIrVb2lFVVOR NUfDTJI3[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg NGT6R|AzPDhzMES5Oy=>
MCF-7  Mn31UY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 MXixNOKhdk1? MljTN:Kh\A>? NU\xWXVXTE2VTx?= MnfnZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi Mn76NlQ5OTB2OUe=
MCF-7 MWHGeY5kfGmxbjDBd5NigQ>? M4X6TFUuPTBibl2= NXrKd2QzOjRiaB?= NGW1[IZFVVOR Ml32doVlfWOnZDD0bIUhdGW4ZXygc4Yh\XiycnXzd4lwdiCxZjDFVu6yNCCSUjDhcoQhTm:6QUJCpC=> M3GxZ|I1OzZ4NEC3
CTS NH;CXpVCeG:ydH;zbZMhSXO|YYm= M{X1NlDjiJN2MDDuUeKh NF3GTmI1QCCq MVnpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkfrNlQzPDR2Mkm=
OCI-AML3  Mlr0RZBweHSxc3nzJGF{e2G7 MmTXNQKBmzRyIH7NxsA> NIH6TXA1QCCq MYfpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Ml7TNlQzPDR2Mkm=
U937 M4PO[GFxd3C2b4Ppd{BCe3OjeR?= MnHaNQKBmzRyIH7NxsA> MnHIOFghcA>? NYOz[2Q2cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHXOfGwzPDJ2NESyPS=>
PC3 M{\XO2Fxd3C2b4Ppd{BCe3OjeR?= MUmwMVExOCCwTR?= M{frWlI1NzR6IHi= MnjhbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NF7tb4czPDF4M{KzNC=>
PC3-AR NYjqXWo4SXCxcITvd4l{KEG|c3H5 MUOwMVExOCCwTR?= NFP6VYMzPC92ODDo MUXpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYWyOFE3OzJ|MB?=
PC3 NUPWO446T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWwMVExOCCwTR?= NIjqPWozPC92ODDo M3zYV4lv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25? NIn2VI4zPDF4M{KzNC=>
PC3-AR MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\sXVAuOTByIH7N NF7yeHAzPC92ODDo M4iyWIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG|ZR?= NISzPJIzPDF4M{KzNC=>
PC3 Mm\CSpVv[3Srb36gRZN{[Xl? NHvlfXAxNTFyMDDuUS=> M3np[|I1KGh? NV;X[nVPe3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> NEHTcGkzPDF4M{KzNC=>
PC3-AR M1u3[GZ2dmO2aX;uJGF{e2G7 MlLxNE0yODBibl2= MUCyOEBp NEL5dWh{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> M3f5OFI1OTZ|MkOw
OS-RC-2 Mn:4R4VtdCCYaXHibYxqfHliQYPzZZk> M{fPV|AuOTByMDDuUS=> NELROYszPC92OD:3NkBp NUPkfFQ2TE2VTx?= MmO3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NEHFR44zPDF2NEezOy=>
OS-RC-2 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW3OVAhdk1? Mlm1OFghcA>? Moi2SG1UVw>? MmLrbY5lfWOnczDHNk9OKGG{cnXzeC=> M3jpUlI1OTR2N{O3
OS-RC-2 M2jHXWFxd3C2b4Ppd{BCe3OjeR?= M1zMVlUxKG6P MY[0PEBp NEf5[5pFVVOR NGDzPI1qdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{[5c|I1OTR2N{O3
SK-N-AS NHnS[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fhV|DjiJN6MDDuUS=> Mnu0OFghcA>? NYnnO|VkUUN3ME2yO{41KG6P NIXWcXgzPDB7OEe5PS=>
SK-N-DZ M{fiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rsS|DjiJN6MDDuUS=> NG\wXVE1QCCq NWXyPFdvUUN3ME2yNU46KG6P MmS5NlQxQTh5OUm=
SK-N-SH NXe1TnZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHZNQKBmzhyIH7N MVO0PEBp M332bGlEPTB;N{KuN{BvVQ>? MUeyOFA6QDd7OR?=
SK-N-BE NFzlW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G0WVDjiJN6MDDuUS=> MXy0PEBp MlLVTWM2OD15NT60JI5O MYWyOFA6QDd7OR?=
SK-N-AS M17WVGFxd3C2b4Ppd{BCe3OjeR?= MW[w5qCUQDBibl2= NIL4blQ1QCCq M3jYOpBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> NYC5S|JKOjRyOUi3PVk>
SK-N-DZ NH\nTYFCeG:ydH;zbZMhSXO|YYm= M1fkbFDjiJN6MDDuUS=> MYq0PEBp NWXlUFhmeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v MmjCNlQxQTh5OUm=
SK-N-SH NFzabnZCeG:ydH;zbZMhSXO|YYm= Mk[xNQKBmzRyIH7N MoDROFghcA>? NEfie4Rxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> MmPGNlQxQTh5OUm=
SK-N-BE M4W3UmFxd3C2b4Ppd{BCe3OjeR?= MlPwNQKBmzRyIH7N MWi0PEBp MoLtdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NGPrenAzPDB7OEe5PS=>
SK-N-AS MlqySpVv[3Srb36gRZN{[Xl? NV;UU5VSOOLCk{iwJI5O M{n6[|Q5KGh? M1vFeYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> NYfKcFJqOjRyOUi3PVk>
SK-N-DZ NGHJWnpHfW6ldHnvckBCe3OjeR?= M{flSVDjiJN6MDDuUS=> M{PZWlQ5KGh? M{K3PIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MlnuNlQxQTh5OUm=
SK-N-SH NV3wN482TnWwY4Tpc44hSXO|YYm= MWGw5qCUPDBibl2= Ml\2OFghcA>? MYTpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ M1zKUlI1ODl6N{m5
SK-N-BE NXX3cW5[TnWwY4Tpc44hSXO|YYm= MknzNQKBmzRyIH7N NV\QTFE1PDhiaB?= M{m0cYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> NEnlSpczPDB7OEe5PS=>
HCC-LM3 NVTacY5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC1NU0yODByIH7N MYqyOE81QC95MjDo MXzEUXNQ NF\nSIFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mn7xNlQxQTN7NU[=
HepG2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DXdlEuOTByMDDuUS=> M4PVO|I1NzR6L{eyJIg> NGH0UHhFVVOR MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVnLepNJOjRyOUO5OVY>
SMMC-7721 M17F[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17OTlEuOTByMDDuUS=> NXvX[IhXOjRxNEivO|IhcA>? M3W3RmROW09? M{G5colvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NV;jRXpsOjRyOUO5OVY>
HCC-LM3 NXjBR4R{SXCxcITvd4l{KEG|c3H5 MkXEOVAhdk1? M3S1b|Q5KGh? NYeyWGZ7TE2VTx?= MnOxbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> M{\BeFI1ODl|OUW2
HepG2 MmjDRZBweHSxc3nzJGF{e2G7 M33Rc|UxKG6P NX72UnZ6PDhiaB?= NE[2RXhFVVOR MlW0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> Ml3iNlQxQTN7NU[=
SMMC-7721 MlnSRZBweHSxc3nzJGF{e2G7 MYK1NEBvVQ>? MXy0PEBp NYr6VoNRTE2VTx?= M3HDNYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 MnPhNlQxQTN7NU[=
HCC-LM3 MoPPSpVv[3Srb36gRZN{[Xl? NUjKVo9RPTBxMUCwJI5O NWPkN2x3OjRiaB?= NWXhcVBiTE2VTx?= MVrk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi MX[yOFA6Ozl3Nh?=
HepG2 MmrpSpVv[3Srb36gRZN{[Xl? M2TGSlUxNzFyMDDuUS=> NFHMWIQzPCCq MkXXSG1UVw>? MnzP[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= MViyOFA6Ozl3Nh?=
SMMC-7721 M1TWWmZ2dmO2aX;uJGF{e2G7 NXn2PYFKPTBxMUCwJI5O MkLmNlQhcA>? NY\DSlZ2TE2VTx?= NV3G[pli\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> NFe0UXAzPDB7M{m1Oi=>
HCC-LM3 MmrzSpVv[3Srb36gRZN{[Xl? M{XRR|UxNzFyMDDuUS=> NFrrZ5czPCCq MljISG1UVw>? MkX5[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? NXrlZ|RtOjRyOUO5OVY>
HepG2 M2G3NGZ2dmO2aX;uJGF{e2G7 M4LOWlUxNzFyMDDuUS=> M{XIblI1KGh? MlHESG1UVw>? NE\STZVld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w MWCyOFA6Ozl3Nh?=
SMMC-7721 MXvGeY5kfGmxbjDBd5NigQ>? M1KyW|UxNzFyMDDuUS=> MUKyOEBp Mo\vSG1UVw>? Mmrn[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? MojuNlQxQTN7NU[=
FaDu NETXTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xNFDjiIWwTR?= MXy4M|ExNzF{IHi= NE\VdY5lcXOybHH5[YQh[SC|aXfubYZq[2GwdDDhcoQheHKxbH;u[4VlKEd{L12gZZJz\XO2IHH0JFgh[W6mIEGy5qCGcCCyb4P0JJJmdGWjc3W= MnfENlQxOjZ2OEK=
FaDu M1TpU2Z2dmO2aX;uJGF{e2G7 M2qze|ExOOLChX7N MX6yM|QwQC9zMjDo M{K4NYlv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w NHXxV2QzPDB{NkS4Ni=>
PC-3  NYTrOppPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7FNE0yOCEQvF2= NGjhW3ozPC92OD:3NkBp NVK3VnRscW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NV3NW2E3OjN7OUGyNVY>
LNCaP Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjJNE02KM7:TR?= NIS1WXYzPC92OD:3NkBp M2H1W4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWmyN|k6OTJzNh?=
RWPE-1  MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6wMVIxKM7:TR?= M1GzflI1NzR6L{eyJIg> MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHP5ZZYzOzl7MUKxOi=>
Capan-1 MV3GeY5kfGmxbjDBd5NigQ>? MV:yOU82OC9zMECgcm0> MYW4M|I1NzR6IHi= M3vaNWROW09? M2XUNYRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= M1;qfVI{QTJ{OEi2
L3.6pl MVfGeY5kfGmxbjDBd5NigQ>? M4HVelI2NzVyL{GwNEBvVQ>? MoHaPE8zPC92ODDo NUnVdIlWTE2VTx?= NWjRWmZJ\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> MkHNNlM6OjJ6OE[=
CFPAC-1  Mmm4SpVv[3Srb36gRZN{[Xl? MkW0NlUwPTBxMUCwJI5O NFHCfZY5NzJ2L{S4JIg> MlPvSG1UVw>? M2D5U4Rwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= Mnv2NlM6OjJ6OE[=
Capan-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e1XVI2NzVyL{GwNEBvVQ>? Ml\lOFghcA>? NYT6WIszTE2VTx?= NV76UGdbemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYKyN|kzOjh6Nh?=
L3.6pl NHPucHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzWNlUwPTBxMUCwJI5O MUi0PEBp NIjIboZFVVOR NEjIU25z\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NUjmWlA2OjN7MkK4PFY>
CFPAC-1  NGfM[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmyOU82OC9zMECgcm0> NYnxPHpIPDhiaB?= MmqzSG1UVw>? NYj5W4k4emWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIfrRpAzOzl{Mki4Oi=>
Capan-1 M1vwOGFxd3C2b4Ppd{BCe3OjeR?= M{PPNlI2NzVyL{GwNEBvVQ>? NVezOopJPDhiaB?= MlnNSG1UVw>? MYrpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Ml3UNlM6OjJ6OE[=
L3.6pl NXvi[ZAxSXCxcITvd4l{KEG|c3H5 M1G4NFI2NzVyL{GwNEBvVQ>? NUHnS|VpPDhiaB?= NFfpepJFVVOR NWna[lhPcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWqyN|kzOjh6Nh?=
CFPAC-1  MYPBdI9xfG:|aYOgRZN{[Xl? MnP6NlUwPTBxMUCwJI5O M37tT|Q5KGh? M2CybGROW09? MVvpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1uzdVI{QTJ{OEi2
HN22 M2LCcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3aTFczOC1{MDDuUS=> M4DpfVI1NzR6IHi= M3HnRWROW09? NELQXYlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz MkL3NlM5Pzd{M{W=
HSC4  NWHTVmFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPXNE0zOCCwTR?= NETzTW4zPC92ODDo M1rTXmROW09? MYfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy NVnPV4xxOjN6N{eyN|U>
HN22 NVnySpNiSXCxcITvd4l{KEG|c3H5 NFHDOm0xNTJyIH7N NVvUW2E3PDhiaB?= NXnuUHJOTE2VTx?= NYTvOlg2cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MnPZNlM5Pzd{M{W=
HSC4  M2HOTmFxd3C2b4Ppd{BCe3OjeR?= M3zjOFAuOjBibl2= NUnLN|lKPDhiaB?= NVLUVnd6TE2VTx?= MmjlbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MXqyN|g4PzJ|NR?=
HN22 MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWwMVIxKG6P M1LNfVQ5KGh? MknRSG1UVw>? NVG5b44zcW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh NHPieY0zOzh5N{KzOS=>
HSC4  MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvaW4dLOC1{MDDuUS=> Mmi5OFghcA>? M4iyVGROW09? NISydolqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> M1i4dFI{QDd5MkO1
HN22 NFfiZ3RHfW6ldHnvckBCe3OjeR?= MYWwMVIxKG6P MkDxOFghcA>? MYjEUXNQ Mn\Hd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg MlvpNlM5Pzd{M{W=
HSC4  M2P6O2Z2dmO2aX;uJGF{e2G7 M4rJ[VAuOjBibl2= NWrHUXA2PDhiaB?= M1jIfWROW09? NYrmdFc{e3WycILld5NmeyCVcEGg[ZhxemW|c3nvcuKh Mk\hNlM5Pzd{M{W=
Cal62 NY\icpRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XnS2lEPTB;M{OgxtEhPCCwTR?= NF7Ed4gzOzh{NEC2OC=>
Hth7 MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nmfWlEPTB;MUWgxtEhOiCwTR?= M1rNfVI{QDJ2ME[0
Hth83 MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTN2INMxJFUhdk1? Mk\jNlM5OjRyNkS=
C643 M2HKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTdzINMxJFExKG6P MXuyN|gzPDB4NB?=
SW1736 M{L4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHUTWM2OD1|NTFCtUA5KG6P MXOyN|gzPDB4NB?=
T241 NUL5fnFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;PRW5KSzVyPU[1JOKyKDdibl2= M4HmdVI{QDJ2ME[0
T351 MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljoTWM2OD13MDFCtUAyOCCwTR?= M1\rUlI{QDJ2ME[0
BHP2-7 NXPkTW84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqyTWM2OD1|NzFCtUA3KG6P NITrWVUzOzh{NEC2OC=>
T238 M3TCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rXSGlEPTB;MTy1NFAhyrFiMkCwJI5O MkOxNlM5OjRyNkS=
HCT8 NYHQV2xQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\qOY1KPzJiaB?= NV7yW|d3TE2VTx?= M2nO[GlEPTB;MUKuPgKBkcLz4pEJNU46KG6P MmXyNlMzQTl|OEi=
H630 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYS3NkBp MmHFSG1UVw>? M{HlZWlEPTB;MUKuOQKBkcLz4pEJN{4yKG6P NEnu[XkzOzJ7OUO4PC=>
cH630 5-FU-res MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS3NkBp M4TI[WROW09? NFPySoVKSzVyPUG1MlXjiIoEsfMAjVEvOiCwTR?= NWfnUWhrOjN{OUmzPFg>
HCT116 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHw[ZBGPzJiaB?= NI\hTVRFVVOR NW\FfnBbUUN3ME2xNE446oDLwsJihKkzNjJibl2= MXSyN|I6QTN6OB?=
HCT116 p53−/− MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\WO|IhcA>? NF3FS29FVVOR MW\JR|UxRThwNvMAjeKy6oDLMT63JI5O M1nWb|I{Ojl7M{i4
dHCT116 p21−/− M3\GTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe3NkBp M3HOTmROW09? NVz6eZRJUUN3ME21MlnjiIoEsfMAjVEvOyCwTR?= NUO0bpA5OjN{OUmzPFg>
HT29 NVzQPZBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DjWlczKGh? MmnaSG1UVw>? M4jZdGlEPTB;MU[uN-KBkcLz4pEJNk4{KG6P MYSyN|I6QTN6OB?=
LoVo NXPNTHVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3NdWNLPzJiaB?= NHHi[5RFVVOR MnzVTWM2OD13LkJihKnDueLCiUCuOkBvVQ>? M13wUVI{Ojl7M{i4
RKO NHnUUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ntUFczKGh? M2rU[mROW09? M{n3eGlEPTB;Nz655qCKyrIkgJmyMlIhdk1? NE[zO3EzOzJ7OUO4PC=>
SW480 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfZZ4dsPzJiaB?= MY\EUXNQ MkHBTWM2OD1zNz615qCKyrIkgJmwMlghdk1? Mn;PNlMzQTl|OEi=
eSW620 NH;oNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWm3NkBp MkCwSG1UVw>? NHfNbXBKSzVyPUmuNgKBkcLz4pEJNk4yKG6P NGHmeHkzOzJ7OUO4PC=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589
Smiles CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04341311 Recruiting Drug: Marizomib|Drug: Panobinostat Diffuse Intrinsic Pontine Glioma|Pediatric Brainstem Glioma|Pediatric Brainstem Gliosarcoma Recurrent|Pediatric Cancer|Pediatric Brain Tumor|Diffuse Glioma Dana-Farber Cancer Institute|Celgene|Secura Bio August 2020 Phase 1
NCT03632317 Withdrawn Drug: Panobinostat|Drug: Everolimus Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Drug: PDR001|Drug: Panobinostat Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT04326764 Recruiting Drug: Panobinostat Acute Myeloid Leukaemia (AML)|Myelodysplastic Syndromes (MDS) Goethe University|Jan J. Cornelissen (HOVON-SAKK)|Sebastian Giebel (PALG) July 24 2018 Phase 3
NCT03515915 Unknown status -- Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID